NO904806L - Rekombinante flagellin-vaksiner. - Google Patents

Rekombinante flagellin-vaksiner.

Info

Publication number
NO904806L
NO904806L NO90904806A NO904806A NO904806L NO 904806 L NO904806 L NO 904806L NO 90904806 A NO90904806 A NO 90904806A NO 904806 A NO904806 A NO 904806A NO 904806 L NO904806 L NO 904806L
Authority
NO
Norway
Prior art keywords
recombinant
epitope
flagellin
proteins
fusion proteins
Prior art date
Application number
NO90904806A
Other languages
English (en)
Other versions
NO302031B1 (no
NO904806D0 (no
Inventor
William Robert Marjarian
Bruce Arnold Dunbar Stocker
Salete Maria Cardozo Newton
Original Assignee
Praxis Biolog Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc, Univ Leland Stanford Junior filed Critical Praxis Biolog Inc
Publication of NO904806D0 publication Critical patent/NO904806D0/no
Publication of NO904806L publication Critical patent/NO904806L/no
Publication of NO302031B1 publication Critical patent/NO302031B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO904806A 1988-05-05 1990-11-05 Rekombinant gen omfattende en nukleotidsekvens som koder for et flagellinfusjonsprotein, genmodifisert mikroorganisme omfattende det rekombinante genet og fremgangsmåte for ekspresjon av det NO302031B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19057088A 1988-05-05 1988-05-05
PCT/US1989/001932 WO1989010967A1 (en) 1988-05-05 1989-05-05 Recombinant flagellin vaccines

Publications (3)

Publication Number Publication Date
NO904806D0 NO904806D0 (no) 1990-11-05
NO904806L true NO904806L (no) 1991-01-03
NO302031B1 NO302031B1 (no) 1998-01-12

Family

ID=22701885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO904806A NO302031B1 (no) 1988-05-05 1990-11-05 Rekombinant gen omfattende en nukleotidsekvens som koder for et flagellinfusjonsprotein, genmodifisert mikroorganisme omfattende det rekombinante genet og fremgangsmåte for ekspresjon av det

Country Status (10)

Country Link
EP (1) EP0419513B1 (no)
JP (1) JP2793673B2 (no)
AT (1) ATE121782T1 (no)
AU (1) AU637049B2 (no)
CA (1) CA1340817C (no)
DE (1) DE68922394T2 (no)
DK (1) DK263390A (no)
FI (1) FI104638B (no)
NO (1) NO302031B1 (no)
WO (1) WO1989010967A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
ES2070312T5 (es) * 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DE69126786T2 (de) * 1990-10-01 1998-01-08 The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain, London Polynukleotidsequenz von salmonella
EP0551325B1 (en) * 1990-10-01 2000-03-15 The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Gvt. Of The U. K. Of Great Britain And N. Ireland Method of testing for salmonella
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
MXPA00012796A (es) * 1999-12-28 2002-05-23 Akzo Nobel Nv Vacuna de salmonella.
JPWO2004055045A1 (ja) * 2002-12-16 2006-04-20 株式会社シーエーエフラボラトリーズ サルモネラ抗原処方物、それを使用した抗体検査キット及びサブユニットワクチン
JP2007535924A (ja) 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
US7888064B2 (en) 2004-12-02 2011-02-15 Csir Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid
AU2005325715B2 (en) 2004-12-16 2011-10-06 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
ES2534332T3 (es) 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
WO2009128950A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
JP2017530114A (ja) 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
EP3221464B1 (en) * 2014-11-18 2022-02-23 The Trustees of Columbia University in the City of New York Detection of analytes using live cells
CN104402974B (zh) * 2014-12-10 2017-11-14 重庆医科大学 一种具有粘膜免疫佐剂活性的多肽及其在制备粘膜免疫佐剂中的用途
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
WO1987002385A1 (en) * 1985-10-11 1987-04-23 Genetics Institute, Inc. Method for producing heterologous proteins
EP0237045B1 (en) * 1986-03-11 1993-10-20 Shionogi & Co., Ltd. DNA encoding flagellin and vector having the same
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation

Also Published As

Publication number Publication date
EP0419513A1 (en) 1991-04-03
FI905441A0 (fi) 1990-11-02
DE68922394D1 (de) 1995-06-01
AU637049B2 (en) 1993-05-20
NO302031B1 (no) 1998-01-12
JP2793673B2 (ja) 1998-09-03
DE68922394T2 (de) 1995-10-05
CA1340817C (en) 1999-11-09
JPH04502402A (ja) 1992-05-07
NO904806D0 (no) 1990-11-05
WO1989010967A1 (en) 1989-11-16
FI104638B (fi) 2000-03-15
ATE121782T1 (de) 1995-05-15
DK263390A (da) 1991-01-04
AU3697989A (en) 1989-11-29
DK263390D0 (da) 1990-11-02
EP0419513B1 (en) 1995-04-26

Similar Documents

Publication Publication Date Title
NO904806L (no) Rekombinante flagellin-vaksiner.
EP2949340A1 (en) Vaccine composition against Streptococcus suis infection
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
PT584348E (pt) Vacina genetica para virus da imunodeficiencia
WO2005046621A3 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
Hajam et al. Co-administration of flagellin augments immune responses to inactivated foot-and-mouth disease virus (FMDV) antigen
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
Muller et al. Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults
CA2158024A1 (en) A mycoplasma gallisepticum antigen, dna encoding the antigen, recombinant vector bearing the dna and recombinant virus utilizing the recombinant vector as well as use thereof
WO1993020846A1 (en) Recombinant influenza vaccines
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
DE69739233D1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
KR920006503A (ko) 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터
Frenchick et al. Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles
FI953371A (fi) TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi
Grosfeld et al. Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus
WO2002032453A1 (fr) Vaccin de synthese pour la lutte contre le virus de la peste porcine classique et son procede de preparation
Jenkins et al. Enhanced delivery systems for enteric antigen uptake in teleosts
WO2000063242A8 (en) Chimeric lyssavirus nucleic acids and polypeptides
DE3582422D1 (de) Biologische zubereitungen.
Ada Desirable immunologic characteristics for the development of an ideal vaccine
Flores et al. Molecular cloning of rotaviral genes: Implications for immunoprophylaxis.
Sereda et al. Immunogenic properties Acanthocheilonema viteae tropomyosin and protective immunity induced against parasite challenge after experimental vaccination
Fathizadeh et al. OJVRTM
Salk et al. Next Steps in the Evolution of Vaccinology

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees